Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in adverse effects compared with topical pimecrolimus; GRADE not reported.
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to lower adverse effects compared with topical tacrolimus (low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide led to lower adverse effects compared with topical ciclosporin; GRADE not reported.
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Adverse event: tremor · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: tremor compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: headache compared with placebo (very low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dizziness compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: dry mouth · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dry mouth compared with placebo (very low certainty).
1 finding from 1 review
Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: drowsiness compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: palpitations · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: palpitations compared with placebo (very low certainty).
1 finding from 1 review
Abdominal pain · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: abdominal pains compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: urinary incontinence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: urinary incontinence compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: drowsiness (gabapentin alone) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day) changes adverse effects: drowsiness (gabapentin alone) compared with placebo (very low certainty).
1 finding from 1 review